# Encoded Therapeutics raises $275M to take Dravet gene therapy into pivotal trial

_Published Friday, September 11, 2026 at 7:18 AM EDT · Capital · Latest · Tier 2 — Notable_

Encoded Therapeutics has raised $275 million to advance ETX101, its gene therapy for Dravet syndrome linked to SCN1A mutations, into a pivotal trial, the company said after presenting phase 1/2 POLARIS results at the European Epilepsy Congress.

The round was co-led by GV and an unidentified healthcare fund, with ARCH Venture Partners, SoftBank Vision Fund 2, Venrock and others participating. Encoded said POLARIS showed a large reduction in seizure frequency versus historical controls over 12 months after the one-shot therapy, plus encouraging developmental gains.

The financing also funds manufacturing scale-up and preclinical candidate ETX301 for post-amputation neuroma pain.

## Sources

- [pharmaphorum](https://pharmaphorum.com/news/encoded-raises-275m-dravet-therapy-and-other-financings)

---
Canonical: https://techandbusiness.org/newswire/3Zr6rRS5gIJk4ZZuLGrepO
Published: 2026-09-11T11:18:26.428Z
Story chronology: 2026-09-11T08:43:43.000Z
Retrieved: 2026-10-27T10:03:07.785Z
Publisher: Tech & Business (techandbusiness.org)